TriangleRelugolix 120 MG [Orgovyx] (NCT06111781)
Relugolix 120 MG [Orgovyx] trial for Prostate Cancer (NCT06111781). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults assigned male at birth, with a prostate, with clinically favorable intermediate-risk prostate cancer but a high-risk Decipher score of at least 0.6. Prior prostate surgery or radiation is excluded.
The idea: test whether 30 days of oral relugolix adds benefit to stereotactic radiation. Relugolix blocks GnRH signaling to lower testosterone. Random assignment compares radiation alone with radiation plus relugolix, started beforehand. Researchers track PSA and quality of life.
This phase 2 study plans 60 patients. Yale’s James Yu leads it; four US sites are recruiting, including New Haven.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.